explore -WSS

explore

author：comprehensive 2025-09-27 16:16:52 - browse：381

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare drug price negotiation continues, as pharma counteroffers

Wikipedia

WSS

The untold story of TV’s first prescription drug ad

WATCH: Why do fingernails fall off when they're damaged?

Streamlined flu vaccines recommended by FDA advisory panel

In areas with more Black doctors, Black people live longer

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Wikipedia

explore

focus

Medicare proposal to cover medical devices draws a mixed reaction

The science behind Janet Jackson's pregnancy at 49

Malaria cases in Florida and Texas: Here’s what you need to know

Longer MASH drug regimen improved liver, Akero study finds

Apple is now the first public company to be valued at $3 trillion

Pregnant women don't need prenatal multivitamins, study concludes

After affirmative action ruling, medical educators look to 'holistic review'

A new approach to psychiatric drug development

BioMarin wins approval for gene therapy to treat hemophilia A

3 hurdles to bringing medical devices to the U.S. market

hotspot

The strategy behind pharma's lawsuits over drug pricing reform

3 hurdles to bringing medical devices to the U.S. market

Families look for replacement for GSK asthma drug Flovent

Medicare drug price negotiation continues, as pharma counteroffers

3 hurdles to bringing medical devices to the U.S. market

#NeedHerScience: shining a light on gender disparities in medicine

knowledge

Wikipedia

knowledge

leisure time